Heart failure in acute ischemic stroke

Current Cardiology Reviews

Volumn 6, Issue 3, 2010, Pages 202-213

  Cuadrado Godia, Elisa ^a   Ois, Angel ^a   Roquer, Jaume ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Heart failure; Outcome; Stroke

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; BISOPROLOL; CARVEDILOL; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ELECTROLYTE; FIBRINOLYTIC AGENT; FIBRINOLYTIC FACTOR; FIBRINOPEPTIDE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METOPROLOL SUCCINATE; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE HEART INFARCTION; AGE; AGING; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; BRAIN EMBOLISM; BRAIN ISCHEMIA; BRAIN PERFUSION; CARDIOVASCULAR RISK; CATHETERIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG MEGADOSE; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAM; ELECTROLYTE BLOOD LEVEL; ENDOTHELIAL DYSFUNCTION; FIBRINOLYTIC THERAPY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE FILLING; HEART VENTRICLE THROMBOSIS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LOW DRUG DOSE; MITRAL VALVE DISEASE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH PROBLEM; RADIOISOTOPE VENTRICULOGRAPHY; RECURRENT DISEASE; REVASCULARIZATION; RHEUMATIC HEART DISEASE; SECONDARY PREVENTION; SINUS RHYTHM; THORAX RADIOGRAPHY; THYROID FUNCTION; URINALYSIS;

EID: 77956530449     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310791658776     Document Type: Article

References (121)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused updateincorporated into the ACC/AHA 2005 Guidelines for the Diagnosisand Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed incollaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease andstroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Sub committee. Circulation 2009; 119: e21-181
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease andStroke Statistics--2010 Update. A Report From the American Heart Association. Circulation 2010; 121: e1-e170
4. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestiveheart failure in US men and women: NHANES I epidemiologicfollow-up study. Arch Intern Med 2001; 161:996-1002
5. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitionsand classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on ClinicalCardiology, Heart Failure and Transplantation Committee; Qualityof Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16
6. Elliott P, Andersson B, Arbustini E, et al. Classification of thecardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-6
7. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic andasymptomatic left-ventricular systolic dysfunction in an urbanpopulation. Lancet 1997; 350:829-33
8. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary tomake the diagnosis of diastolic heart failure? Circulation 2001;104:779-82
9. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail 2007; 9: 136-43
10. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and out come of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9
11. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-27
12. Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344:17-22
13. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagno sediastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echo cardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-50
14. Yancy CW, Lopatin M, Stevenson LW, et al. ADHERE ScientificAdvisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47:76-84
15. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl JMed 2006; 355:260-9
16. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008; 10: 149-56
17. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acutedyspnea. N Engl J Med 2004; 350: 647-54
18. Cheitlin MD, Armstrong WF, Aurigemma GP, et al.ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association TaskForce on Practice Guidelines (ACC/AHA/ASE Committee toUpdate the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echo cardiogr 2003; 16:1091-110
19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8
20. Roy D, Talajic M, Dubuc M, et al. Atrial fibrillation and congestive heart failure. Curr Opin Cardiol 2009; 24:29-34
21. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69:546-54
22. Witt BJ, Brown RD, Jr, Jacobsen SJ, et al. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006; 152:102-9
23. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation isassociated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am CollCardiol 1998; 32: 695-703
24. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251-7
25. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2007; 115: 2637-41
26. Andersson B, Waagstein F. Spectrum and outcome of congestiveheart failure in a hospitalized population. Am Heart J 1993; 126:632-40
27. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome ofcongestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study.Ann Intern Med 2002; 137: 631-9
28. Jelinek MV, Ansari MZ. Congestive cardiac failure (CCF) as acause of fatal stroke and all cause death. Aust N Z J Med 1998; 28:799-804
29. Effect of ramipril on mortality and morbidity of survivors of acutemyocardial infarction with clinical evidence of heart failure. TheAcute Infarction Ramipril Efficacy (AIRE) Study Investigators.Lancet 1993; 342: 821-8
30. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302
31. Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril SurvivalStudy (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429-35
32. Witt BJ, Gami AS, Ballman KV, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489-96
33. Pullicino PM, McClure LA, Wadley VG, et al. Blood pressure and stroke in heart failure in the reasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke 2009; 40:3706-10
34. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54:288-94
35. Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolicdys function and the risk of ischemic stroke in a multiethnic population. Stroke 2006; 37:1715-9
36. Adams HP, Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in amulticenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
37. Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688-97
38. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-31
39. Komajda M, Jais JP, Reeves F, et al. Factors predicting mortality in idiopathic dilated cardiomyopathy. Eur Heart J 1990; 11: 824-31
40. Shaper AG, Phillips AN, Pocock SJ, et al. Risk factors for stroke in middle aged British men. BMJ 1991; 302: 1111-5
41. Bots ML, Nikitin Y, Salonen JT, et al. Left ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: acollaborative study among research centres in Europe.J.Epidemiol.Community Health 2002; 56 (Suppl 1): 8-13
42. Kohsaka S, Sciacca RR, Sugioka K, et al. Additional impact of electrocardiographic over echocardiographic diagnosis of left ventricular hypertrophy for predicting the risk of ischemic stroke.Am Heart J 2005; 149: 181-6
43. Pop GA, Koudstaal PJ, Meeder HJ, et al. Predictive value of clinical history and electrocardiogram in patients with transientischemic attack or minor ischemic stroke for subsequent cardiac and cerebral ischemic events. The Dutch TIA Trial Study Group.Arch Neurol 1994; 51: 333-41
44. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study.JAMA 1994; 272: 33-6
45. Fox ER, Alnabhan N, Penman AD, et al. Echo cardiographic left ventricular mass index predicts incident stroke in African Americans: Atherosclerosis Risk in Communities (ARIC) Study.Stroke 2007; 38: 2686-91
46. Verma A, Meris A, Skali H, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT [VALsartan In Acute myocardial iNfarcTion] Echocardiographic Study. JACC Cardiovasc Imaging 2008; 1:582-91
47. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echo cardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-6
48. Di Tullio MR, Zwas DR, Sacco RL, et al. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 2003;34: 2380-4
49. Bluemke DA, Kronmal RA, Lima JA, et al. The relationship of leftventricular mass and geometry to incident cardiovascular events:the MESA (Multi-Ethnic Study of Atherosclerosis) study. J AmColl Cardiol 2008; 52: 2148-55
50. Muiesan ML, Salvetti M, Paini A, et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007; 49: 1077-83
51. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression ofechocardiographic left ventricular hypertrophy after 2 years oftherapy reduces cardiovascular risk in patients with essentialhypertension. Am J Hypertens 2008; 21: 464-70
52. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascularrisk by regression of electrocardiographic markers of leftventricular hypertrophy by the angiotensin-converting enzymeinhibitor ramipril. Circulation 2001; 104: 1615-21
53. Okin PM, Devereux RB, Jern S, et al. Regression of electro-cardiographic left ventricular hypertrophy during anti hypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-9
54. Verdecchia P, Angeli F, Gattobigio R, et al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006; 19:493-9
55. Rodriguez CJ, Sacco RL, Sciacca RR, et al. Physical activity attenuates the effect of increased left ventricular mass on the risk of is chemic stroke: The Northern Manhattan Stroke Study. J Am Coll Cardiol 2002; 39: 1482-8
56. Gardin JM, McClelland R, Kitzman D, et al. M-modeecho cardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort [the Cardiovascular Health Study].Am J Cardiol 2001; 87: 1051-7
57. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-84
58. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-52
59. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am CollCardiol 1995; 25: 871-8
60. Pierdomenico SD, Lapenna D, Bucci A, et al. Prognostic value of left ventricular concentric remodeling in uncomplicated mild hypertension. Am J Hypertens 2004; 17: 1035-9
61. Muiesan ML, Salvetti M, Monteduro C, et al. Left ventricular concentric geometry during treatment adversely affects cardio vascular prognosis in hypertensive patients. Hypertension 2004; 43:731-8
62. Kalaria VG, Passannante MR, Shah T, et al. Effect of mitralregurgitation on left ventricular thrombus formation in dilated cardiomyopathy. Am Heart J 1998; 135: 215-20
63. Jafri SM. Hypercoagulability in heart failure. Semin Thromb Hemost 1997; 23: 543-5
64. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuro endocrine activity in heart failure. Am Heart J 1994; 127: 607-12
65. Georgiadis D, Sievert M, Cencetti S, et al. Cerebro vascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000; 21: 407-13
66. Choi BR, Kim JS, Yang YJ, et al. Factors associated with decreased cerebral blood flow in congestive heart failure secondaryto idiopathic dilated cardiomyopathy. Am J Cardiol 2006; 97:1365-9
67. Zuccala G, Onder G, Pedone C, et al. Hypotension and cognitive impairment: Selective association in patients with heart failure.Neurology 2001; 57:1986-92
68. Caplan LR. Brain embolism, revisited. Neurology 1993; 43: 1281-7
69. Pullicino P, Mifsud V, Wong E, et al. Hypoperfusion-relatedcerebral ischemia and cardiac left ventricular systolic dysfunction. J Stroke Cerebrovasc Dis 2001; 10: 178-82
70. Caplan LR, Hennerici M. Impaired clearance of emboli [washout]is an important link between hypoperfusion, embolism, and is chemic stroke. Arch Neurol 1998; 55: 1475-82
71. Levy D, Anderson KM, Savage DD, et al. Echocardiographicallydetected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13
72. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke:a risk profile from the Framingham Study. Stroke 1991; 22: 312-18
73. Kronmal RA, Smith VE, O'Leary DH, et al. Carotid arterymeasures are strongly associated with left ventricular mass in older adults (a report from the Cardiovascular Health Study). Am J Cardiol 1996; 77: 628-33
74. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: asystematic review and meta-analysis. Circulation 2007; 115: 459-67
75. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascularevent rates in outpatients with atherothrombosis. JAMA 2007; 297:1197-206
76. Kohara K, Zhao B, Jiang Y, et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebro vascular damage in essential hypertension. Am J Cardiol 1999; 83: 367-70
77. Arboix A, Marti-Vilalta JL. Lacunar stroke. Expert Rev Neurother 2009; 9: 179-96
78. Wardlaw JM. What causes lacunar stroke? J Neurol Neurosurg Psychiatry 2005; 76: 617-9
79. Palomeras E, Roquer J, Pou A. et al. Ictus y fibrilación auricular.Neurologia 2000; 15: 51-7
80. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, andtreatment in subtypes of ischemic stroke: the German stroke databank. Stroke 2001; 32: 2559-66
81. Ois A, Cuadrado-Godia E, Jimenez-Conde J, et al. Early arterial study in the prediction of mortality after acute ischemic stroke. Stroke 2007; 38: 2085-9
82. Petty GW, Brown RD, Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-8
83. Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute is chemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333-7
84. Sharma J, Fletcher S, Vassallo M, et al. Characteristics and outcome of acute stroke patients not investigated with computerised tomography scan. Gerontology 2002; 48: 321-4
85. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34
86. Anderson CS, Jamrozik KD, Broadhurst RJ, et al. Predictingsurvival for 1 year among different subtypes of stroke. Results from the Perth Community Stroke Study. Stroke 1994; 25: 1935-44
87. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000; 31: 2080-6
88. Appelros P, Nydevik I, Seiger A, et al. Predictors of severe stroke: influence of preexisting dementia and cardiac disorders. Stroke 2002; 33: 2357-62
89. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7
90. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003; 34:122-6
91. Putaala J, Curtze S, Hiltunen S, et al. Causes of death and predictors of 5-year mortality in young adults after first-ever is chemic stroke: the Helsinki Young Stroke Registry. Stroke 2009;40: 2698-703
92. Ois A, Gomis M, Cuadrado-Godia E, et al. Heart failure in acute ischemic stroke. J Neurol 2008; 255: 385-9
93. Brott T, Adams HP, Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-70
94. Ois A, Gomis M, Rodriguez-Campello A, et al. Factors associated with a high risk of recurrence in patients with transient is chemic attack or minor stroke. Stroke 2008; 39: 1717-21
95. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34
96. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial function and mortality risk in patients with chronic heart failure.Circulation 2005; 111: 310-4
97. Ward RP, Don CW, Furlong KT, et al. Predictors of long-term mortality in patients with ischemic stroke referred for transesophageal echocardiography. Stroke 2006; 37: 204-8
98. Roquer J, Ois A, Rodriguez-Campello A, et al. Atheroscleroticburden and early mortality in acute ischemic stroke. Arch Neurol 2007; 64: 699-704
99. Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary riskevaluation in patients with transient ischemic attack and ischemicstroke: a scientific statement for healthcare professionals from theStroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003; 108:1278-90
100. Touze E, Varenne O, Chatellier G, et al. Risk of myocardial infarction and vascular death after transient ischemic attack and is chemic stroke: a systematic review and meta-analysis. Stroke 2005; 36: 2748-55
101. Prosser J, MacGregor L, Lees KR, et al. Predictors of early cardiac morbidity and mortality after ischemic stroke. Stroke 2007; 38:2295-302
102. Makikallio AM, Makikallio TH, Korpelainen JT, et al.Natriuretic peptides and mortality after stroke. Stroke 2005; 36: 1016-20
103. Kerr G, Ray G, Wu O, et al. Elevated tropon in after stroke: a systematic review. Cerebrovasc Dis 2009; 28: 220-6
104. Jensen JK, Kristensen SR, Bak S, et al. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardio 2007; 99: 108-12
105. Oppenheimer SM. Neurogenic cardiac effects of cerebro vascular disease. Curr Opin Neurol 1994; 7: 20-4
106. Wang TD, Wu CC, Lee YT. Myocardial stunning after cerebral infarction. Int J Cardiol 1997; 58: 308-11
107. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemicstroke and transient is chaemic attack 2008. Cerebrovasc Dis 2008;25: 457-507
108. Roquer J, Rodriguez-Campello A, Gomis M, et al. Acute stroke unit care and early neurological deterioration in ischemic stroke. J Neurol 2008; 255: 1012-17
109. Sare GM, Geeganage C, Bath PM. High blood pressure in acuteis chaemic stroke--broadening therapeutic horizons. Cerebrovasc Dis 2009; 27 (Suppl 1): 156-61
110. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-49
111. Schulman DS, Flores AR, Tugoen J, et al. Antihypertensive treatment in hypertensive patients with normal left ventricular mass is associated with left ventricular remodeling and improved diastolic function. Am J Cardiol 1996; 78: 56-60
112. Lakhan SE, Sapko MT. Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. Int Arch Med 2009; 2: 30
113. Laowattana S, Oppenheimer SM. Protective effects of beta-blockers in cerebro vascular disease. Neurology 2007; 68: 509-14
114. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30: 527-32
115. Holmang A, Yoshida N, Jennische E, et al. The effects ofhyperinsulinaemia on myocardial mass, blood pressure regulation and central haemo dynamics in rats. Eur J Clin Invest 1996; 26:973-8
116. Petty GW, Brown RD, Jr, Whisnant JP, et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50:208-16
117. Pullicino P, Thompson JL, Mohr JP, et al. Oral anticoagulation inpatients with cardiomyopathy or heart failure in sinus rhythm.Cerebrovasc Dis 2008; 26: 322-7
118. Hirsh J, Fuster V, Ansell J, et al. American Heart Association, American College of Cardiology Foundation. American HeartAssociation/American College of Cardiology Foundation guide towarfarin therapy. Circulation 2003; 107:1692-711
119. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058-67
120. Massie BM, Collins JF, Ammon SE, et al. Randomized trial ofwarfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-24
121. Pullicino P, Thompson JL, Barton B, et al. Warfarin versus aspirinin patients with reduced cardiac ejection fraction (WARCEF):rationale, objectives, and design. J Card Fail 2006; 12: 39-46.